MPS Limited has informed the Exchange regarding 'Transcript of the Conference Call on the Acquisition of Unbound Medicine, Inc., USA'.
MPSLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
MPS Limited has completed the acquisition of Unbound Medicine, a US-based healthcare knowledge management platform, through its wholly-owned subsidiary MPS North America LLC for a final transaction value of around USD 15.18 million, funded partly through INR 42 crores of debt. Unbound reported revenue of approximately USD 8.88 million in 2024 with a standalone EBITDA margin of around 14%, serving over 1,000 healthcare facilities and around 90,000 paid subscribers with a 97% subscription retention rate. Management has guided that margins will move from 14% to the early 20s within a quarter and reach MPS's average level of around 30% by the exit of FY27 Q4, while revenue is expected to roughly double over the next few years via geographic expansion outside North America. The acquisition is part of the Vision 2027 target of INR 1,500 crores revenue at similar margins, with management noting 5 deals at an advanced stage and 2 near completion in the pipeline. Capital distribution through dividends and buybacks is expected to continue as the new debt level is described as comfortable.
Positive near-term for shareholders as the deal adds a high-margin recurring revenue business and a clear margin expansion roadmap; investors should watch for execution on geographic expansion outside North America and progress on the pending acquisitions. Continued dividend and buyback support should cushion any short-term dilution from the INR 42 crore debt raise.